Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris - PubMed (original) (raw)

Review

Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris

L M Hollingshead et al. Drugs. 1992 Nov.

Abstract

Bepridil is a calcium antagonist with direct negative chronotropic, dromotropic, inotropic and vasodilatory actions which reduces myocardial oxygen consumption and increases coronary blood flow, leading to a significant anti-ischaemic and antianginal effect in the absence of reflex tachycardia. In contrast to other calcium channel blockers, bepridil produces only modest peripheral vasodilatation and displays weak antihypertensive activity. Its plasma elimination half-life of 1 to 2 days permits once daily administration. Results of short term clinical trials have shown bepridil to be of comparable efficacy to nifedipine, verapamil, diltiazem, propranolol and nadolol in decreasing the frequency of anginal attacks and consumption of nitroglycerin (glyceryl trinitrate) in patients with stable angina. Bepridil is more effective than nifedipine in improving exercise performance in patients with stable angina. Although bepridil proved superior to diltiazem in improving exercise performance in patients refractory to diltiazem, further studies are required to confirm the efficacy of bepridil in patients refractory to, or intolerant of, other antianginal agents. Bepridil in therapeutic doses is well tolerated, and appears to have a similar adverse effect profile to the established calcium antagonists. However, rate-dependent prolongation of the QTc interval and development of torsade de pointes have been associated with the use of bepridil. Therefore, bepridil is contraindicated in patients with hypokalaemia, those receiving other drugs that may prolong the QT interval, and those with congenital QT interval prolongation. Future clinical research will help to further define the position of bepridil as an antianginal treatment relative to the traditional calcium antagonists; in the interim, bepridil is indicated for the treatment of patients with angina refractory to or intolerant of other agents.

PubMed Disclaimer

Similar articles

• Bepridil treatment of chronic stable angina: a review of comparative studies versus placebo, nifedipine, and diltiazem.
  DiBianco R. DiBianco R. Am J Cardiol. 1992 Apr 9;69(11):56D-62D. doi: 10.1016/0002-9149(92)90960-7. Am J Cardiol. 1992. PMID: 1532468
• Effects of bepridil and diltiazem on ventricular repolarization in angina pectoris.
  Funck-Brentano C, Coudray P, Planellas J, Motté G, Jaillon P. Funck-Brentano C, et al. Am J Cardiol. 1990 Oct 1;66(10):812-7. doi: 10.1016/0002-9149(90)90357-7. Am J Cardiol. 1990. PMID: 2220578 Clinical Trial.
• Bepridil: a new long-acting calcium channel blocking agent.
  Zeller FP, Spinler SA. Zeller FP, et al. Drug Intell Clin Pharm. 1987 Jun;21(6):487-92. doi: 10.1177/106002808702100601. Drug Intell Clin Pharm. 1987. PMID: 3301244 Review.

Cited by

• Post-surgical adhesions are triggered by calcium-dependent membrane bridges between mesothelial surfaces.
  Fischer A, Koopmans T, Ramesh P, Christ S, Strunz M, Wannemacher J, Aichler M, Feuchtinger A, Walch A, Ansari M, Theis FJ, Schorpp K, Hadian K, Neumann PA, Schiller HB, Rinkevich Y. Fischer A, et al. Nat Commun. 2020 Jun 17;11(1):3068. doi: 10.1038/s41467-020-16893-3. Nat Commun. 2020. PMID: 32555155 Free PMC article.
• KCNT1 Channel Blockers: A Medicinal Chemistry Perspective.
  Di Matteo F, Mancuso F, Turcio R, Ciaglia T, Stagno C, Di Chio C, Campiglia P, Bertamino A, Giofrè SV, Ostacolo C, Iraci N. Di Matteo F, et al. Molecules. 2024 Jun 20;29(12):2940. doi: 10.3390/molecules29122940. Molecules. 2024. PMID: 38931004 Free PMC article. Review.
• Antagonist molecules in the treatment of angina.
  Gupta AK, Winchester D, Pepine CJ. Gupta AK, et al. Expert Opin Pharmacother. 2013 Dec;14(17):2323-42. doi: 10.1517/14656566.2013.834329. Epub 2013 Sep 18. Expert Opin Pharmacother. 2013. PMID: 24047238 Free PMC article. Review.
• Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase.
  Capell A, Liebscher S, Fellerer K, Brouwers N, Willem M, Lammich S, Gijselinck I, Bittner T, Carlson AM, Sasse F, Kunze B, Steinmetz H, Jansen R, Dormann D, Sleegers K, Cruts M, Herms J, Van Broeckhoven C, Haass C. Capell A, et al. J Neurosci. 2011 Feb 2;31(5):1885-94. doi: 10.1523/JNEUROSCI.5757-10.2011. J Neurosci. 2011. PMID: 21289198 Free PMC article.
• Bepridil, a class IV antiarrhythmic agent, can block the TREK-1 potassium channel.
  Wang Y, Fu Z, Ma Z, Li N, Shang H. Wang Y, et al. Ann Transl Med. 2021 Jul;9(14):1123. doi: 10.21037/atm-20-7971. Ann Transl Med. 2021. PMID: 34430564 Free PMC article.

References

1. 1. Arch Int Pharmacodyn Ther. 1978 May;233(1):65-75 - PubMed
2. 1. Cardiovasc Drugs Ther. 1989 Oct;3(5):731-42 - PubMed
3. 1. Biochem Pharmacol. 1990 Oct 1;40(7):1615-22 - PubMed
4. 1. Ann Cardiol Angeiol (Paris). 1982 Jul-Sep;31(5):409-15 - PubMed
5. 1. Biochem Pharmacol. 1986 Jan 15;35(2):217-20 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information